Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study

Table 1 Baseline characteristics of the study population, n = 37

Quantitative variable	Median (range)/n	IQR/percent (%)
Age in years	39 (17-64)	32
Disease duration in years	6 (1-28)	13
BMI in kg/m2	23.35 (14.00-36.30)	10.76
Number of previous treatments	2 (0-4)	1
CRP in mg/dL	8.6 (0.5-61.6)	13.98
Albumin in g/dL	4.1 (3.0-5.2)	0.33
Hb in g/dL	13.3 (8.9-15.7)	1.68
PLT as × 109/L	315 (127-705)	181.25
WBC per mL	8935 (4400-16990)	2760.7
Granulocytes (absolute count) per mL	5300.0 (2600.0-11060.5)	2526.4
UCEIS	6.5 (2.0-10.0)	3
Total Mayo score	9 (5-12)	4
NANCY score	3 (3-4)	1
Sex as male/female	19/18	51.4/48.6
Montreal classification as E1/E2/E3	0/10/27	0/27/73
Family history of IBD	3	8.1
Smoking as current/in the past	4/7	10.8/18.9
Extraintestinal manifestations	11	29.7
Musculoskeletal as peripheral arthritis/axonal arthritis/both	6/2/1	16.2/5.4/2.7
Dermatological as pyoderma gangrenosum/psoriasis	1/1	2.7/2.7
Liver/biliary	0	0
Stomal	0	0
Ocular (uveitis)	1	2.7
Other	0	0
Active extraintestinal manifestation	6	16.2
Previous treatment	32	86.5
Steroids	33	89.2
5-ASA	30	81.1
Azathioprine	18	48.6
MTX	2	5.4
Biologics	33	89.2
Anti-TNFα as infliximab/adalimumab/golimumab	29 (24/11/5)	78.4 (64.9/29.7/13.5)
Vedolizumab	19	51.4
Anti-IL12/23	6	16.2
Bloody stool
Traces of blood < 50%	11	29.7
Blood > 50%	22	9.5
Only blood	1	2.7
Number of bowel movements
1-2 more than normal	6	16.2
3-4 more than normal	17	45.9
≥ 5 more than normal	13	35.1
PGA
Mild disease	8	21.6
Moderate disease	14	37.8
Severe disease	15	40.5
Urgency
In 5 minutes	15	40.5
In 1 minute	3	8.1
Incontinence	3	8.1
5-ASA coadministration	20	54.1
Steroids coadministration	23	62.2
Endoscopic Mayo score as 0/1/2/3	1/0/11/19	2.7/0/29.7/51.4

BMI: Body mass index; CRP: C-reactive protein; Hb: Hemoglobin; PLT: Platelets; WBC: White blood counts; UCEIS: Ulcerative Colitis Endoscopic Index of Severity; IBD: Inflammatory bowel disease; 5-ASA: 5-aminosalicylic acid; anti-TNFα: Anti-tumor necrosis factor alpha; IL: Interleukin; MTX: Methotrexate; PGA: Physician’s global assessment; IQR: Interquartile range.